Government specifications on the oxygen content of motor gasoline sold
in certain areas of the USA have resulted in commercialization of the
oxygenate fuel additives tertiary amyl methyl ether (TAME) and ethyl
tertiary butyl ether (ETBE). TAME and ETBE were evaluated in 4-week ra
t inhalation studies sponsored by Amoco Corporation. Target vapor conc
entrations were 0, 500, 2000, or 4000 ppm for 6 h per day, 5 days per
week, for 4 weeks. TAME exposure at 4000 ppm resulted in 25% mortality
, apparently as a consequence of severe CNS depression. Body weight ga
in was decreased in the TAME high dose male rats. In contrast, no ETBE
exposed animals died during the study and no changes in body weight g
ain were observed. Significant effects on functional observational bat
tery (FOE) parameters were only found in the TAME high and mid-dose gr
oups immediately after exposure, All affected FOE parameters were norm
al by the next day. Both TAME and ETBE exposures significantly increas
ed relative liver weights in the high and mid-dose groups. However, no
treatment-related histopathologic findings were noted for either comp
ound. Clinical chemistry and hematology findings were absent with ETBE
exposure and minimal with TAME exposure. The results indicate that 50
0 ppm was a NOAEL for both compounds in these studies.